Calidi Biotherapeutics Taps SIGA Technologies to Boost Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that it entered into a collaboration agreement with SIGA Technologies (NASDAQ:SIGA) in the first quarter of 2024, to support the development of Calidi's systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types. Calidi will initially focus on developing the RTNova platform for lung cancer and metastatic (or advanced stage) solid tumors which account for the majority of cancer deaths.
The long-term collaboration between Calidi and SIGA aims to harness the capabilities of SIGA's TPOXX, an antiviral agent effective against vaccinia virus. The initial focus for the collaboration will be on testing the capacity of TPOXX to become a safety switch to manage RTNova's spread in vivo.
